



Lantheus Collaboration Overview

PNT2002 & PNT2003

November 14, 2022



Legal Disclaimer

Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Global Inc.


This information contained in this presentation does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer, buy or subscribe for, any securities, nor shall there be any offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning the following include forward-looking statements: the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and preclinical studies; the potential attributes and benefits of product candidates, including with respect to radioligand selectivity, activity, side effect and tolerability profile and relevant indications; ability to compete with other companies currently marketing or engaged in the development of treatments for relevant indications; the Company’s expected manufacturing and commercial strategy; the size and growth potential of the markets for product candidates and ability to serve those markets; and the rate and degree of market acceptance of product candidates, if approved. In some cases you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in our Annual Report on Form 10-K filed with the SEC on March 25, 2022. These forward-looking statements are based upon estimates and assumption that, while considered reasonable by POINT and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, factors associated with companies, such as the Company, that are engaged in clinical trials in the pharmaceutical industry, including uncertainty in the timing or results of clinical trials, product acceptance and/or receipt of regulatory approvals for product candidates, risks related to POINT’s ability to successfully develop and launch a commercial product and achieve market acceptance, raise additional funds that may be necessary for the operations of its business and product development, establish manufacturing capacity, manage its operations and potential growth and scale its business, protect its intellectual property, and the potential impact of the COVID-19 pandemic, as well as various other factors beyond management’s control, including general economic conditions. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company undertakes no duty to update these forward-looking statements.



POINT Biopharma: discovering, developing & supplying next generation radioligands™

Robust isotope supply chain



Fortified supply chain,
safeguarded from
disruptions

Commercial scale manufacturing



Internal manufacturing
capabilities, ensuring patients
needs are always met

Radiochemistry & preclinical expertise



Experience engineering
optimized combinations of
ligands, linkers and isotopes

Next generation clinical programs



Currently in the clinic
in indications of high
unmet need



Strategic collaboration with Lantheus leverages core competencies and maximizes value for patients and shareholders

1. Pairs PNT2002/PNT2003 with an ideal partner for commercial success

Industry leading radiopharmaceutical company and the leader in US PSMA PET imaging

2. Offsets commercial launch and market execution risks

While maintaining a significant share of financial success

3. Focuses resources strategically on next-generation opportunities

Including high potential programs like pan-tumor PNT2004 and actinium-labeled PNT2001

4. Bolsters balance sheet

Mitigates the need for further dilutive capital raises to execute on our existing business plans

5. Affirms the value of POINT's platform

Establishes radioligand manufacturing and supply as a specialized business unit
Existing programs and infrastructure remain 100% POINT owned and operated



POINT evaluated multiple strategic pathways prior to identifying Lantheus as the ideal partner to license both PNT2002 & PNT2003




Experienced radiopharma sales organization



With more than 65 years in the field, Lantheus has a deep understanding of the complexities of radiopharma commercialization and long-standing channel relationships

Established presence in prostate & neuroendocrine



Lantheus owns both PYLARIFY, a best-in-class PSMA PET imaging product, and AZEDRA, a therapeutic radioligand approved for certain neuroendocrine tumors

Existing working relationship with cross functional familiarity



POINT has been a partner of and worked with Lantheus for years: in PNT2002's SPLASH clinical trial Lantheus' PYLARIFY is utilized for patient imaging



The strategic collaboration with Lantheus has the potential to create significant shareholder value

	PNT2002	PNT2003
Geography	Exclusive worldwide rights excluding certain territories ¹	
Upfront Payment	\$250M	\$10M
U.S. Regulatory Milestone	Range: \$150M - \$250M (Based on timing of FDA approval and number of competing ¹⁷⁷ Lu-radioligand therapies on market at time of approval)	Up to \$30M in the aggregate
Commercial Sales Milestones: (One-time Calendar Year Net Sales)	\$50M at \$150M net sales \$50M at \$300M net sales \$280M at \$500M net sales	\$150M at \$600M net sales \$250M at \$1,000M net sales \$500M at \$2,000M net sales
Royalties	20% net sales ² royalty (Following commercial launch, Lantheus will pay POINT royalties of 20% of "Eligible Net Sales"; after Lantheus has realized \$500M in cumulative Gross Profit, Lantheus will pay POINT royalties of 20% of "Net Sales")	15% net sales ² royalty
Sublicense Income Sharing	POINT receives 40% of Sublicensing Income (Income not otherwise subject to royalty payments to POINT)	POINT receives 40% of Sublicensing Income (Income not otherwise subject to royalty payments to POINT)
Product Cost	PNT to supply Lantheus with commercial product at COGS + markup	

1. POINT retains the following territories: Japan, South Korea, China (including Hong Kong, Macau and Taiwan), Singapore, and Indonesia

2. Net Sales by Lantheus in Territory and Net Sales by Lantheus/Sublicensee in US


POINT & Lantheus will form joint steering committees to oversee clinical trials, regulatory filings, and manufacturing and commercial readiness



Clinical Development	PNT2002	Complete SPLASH clinical trial Steering Committee Participation	File NDA
	PNT2003	Steering Committee Participation	File for regulatory approval
Manufacturing	PNT2002	All commercial drug supply (US)*	Steering Committee Participation
	PNT2003	All commercial drug supply (US)*	Steering Committee Participation
Commercial	PNT2002	Steering Committee Participation	Lead all commercial efforts
	PNT2003	Steering Committee Participation	Lead all commercial efforts

* Preparation of POINT's Indianapolis production facility for commercial production will be funded using a portion of the upfront payments for PNT2002 & PNT2003. POINT has the right, at its option, to be the supplier of drug for Lantheus and its Sublicensees in other Lantheus Territories

This collaboration enables POINT to strategically invest in new isotopes, opportunistic partnerships, and current and additional programs



Expand isotope “tool chest” to include new, high potential isotopes like terbium-161



Engage in new partnerships and in-licensing opportunities which are synergistic with POINT’s platform

Programs

Discovery	Preclinical	Phase 1	Phase 2	Phase 3

Expand clinical trials to include new indications and combination approaches, and increase investment in discovery capabilities